Why is Erik Digman Wiklund, CFO of Targovax, reading Labiotech.eu?

Leaders & Readers: I had a chat with Erik Digman Wiklund about why he reads Labiotech.eu. He is the CFO of Targovax, a clinical-stage company focusing on the development of immuno-oncology therapies.

This interview has just been lightly edited for grammar.

Why do you read Labiotech.eu?

I enjoy the easygoing and fun style of Labiotech, which is a refreshing change from the many dry industry publications. Also, what differentiates Labiotech is the variety of topics, and that you offer op-ed pieces that go beyond straight news coverage.  

How often do you read Labiotech.eu?

I check the webpage for updates about 1-2 times per week.

How did you first hear about us?

I was introduced to Labiotech through an interview for an article with your editor Evelyn Warner.

(Have a read of the interview here – These Norwegian Biotech Execs are Bringing Back Cancer Vaccines & Oncolytic Viruses)

What’s your favourite article?

I really like the biotech map, a very useful tool! Otherwise, the top 7 EU biotechs of all time is an article I remember and went back to reread.

(You can have a look and play around with the Labiotech map,  and don’t miss having a read of the article, ‘The 7 Best Biotech Companies in Europe’s History’.)

What else do you read in biotech/science?

I track the news on Fiercebiotech most days, and also routinely read Endpoints News and Mednous.

Is there any specific topic you wish to see more of?

  • A weekly synthesis of the top industry news and events – how about in the form of a podcast?
  • More coverage on how investors and big pharma B&D think and work
  • Immuno-oncology.

Many thanks to Erik! Now, I would love to hear why you read Labiotech.eu, just comment below or send me an email to katherine-at-labiotech.eu 😉

Support good journalism, subscribe to Labiotech Insider

Labiotech Insider

If you liked this post and want to read more good journalism, support us by joining Labiotech Insider. Our Insider membership gives you access to exclusive content and other advantages.